Search research articles
Contact Us
Filters
Showing results (21-30 of 65) with videos related to
Page
of 7
Sort By:
Oncology (Williston Park, N.Y.)
|
May 23, 1998
Clinical trials referral resource. Tumor Vaccine Trials
H Streicher, M Sznol, G L Blatner, et al.
Cancer
|
April 15, 1995
A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer
D W Fennelly, L Norton, M Sznol, et al.
The Journal of Clinical Investigation
|
April 20, 2000
Use of preferentially replicating bacteria for the treatment of cancer
M Sznol, S L Lin, D Bermudes, et al.
The Cancer Journal From Scientific American
|
February 11, 1998
High-dose aldesleukin in renal cell carcinoma: long-term survival update
R I Fisher, S A Rosenberg, M Sznol, et al.
Human Gene Therapy
|
January 1, 1995
A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401
R T Fenton, M Sznol, D G Luster, et al.
Annals of Internal Medicine
|
July 15, 1989
Adrenal insufficiency and interleukin-2 therapy
L A VanderMolen, J W Smith, D L Longo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1995
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
G Fyfe, R I Fisher, S A Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1996
Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy
G A Fyfe, R I Fisher, S A Rosenberg, et al.
Cancer Research
|
May 1, 1992
Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study
W J Urba, C Ewel, W Kopp, et al.
Cancer Research
|
May 15, 1990
Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine
W J Urba, L C Hartmann, D L Longo, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 65) with videos related to
Sort By:
Page
of 7
Oncology (Williston Park, N.Y.)
|
May 23, 1998
Clinical trials referral resource. Tumor Vaccine Trials
H Streicher, M Sznol, G L Blatner, et al.
Cancer
|
April 15, 1995
A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer
D W Fennelly, L Norton, M Sznol, et al.
The Journal of Clinical Investigation
|
April 20, 2000
Use of preferentially replicating bacteria for the treatment of cancer
M Sznol, S L Lin, D Bermudes, et al.
The Cancer Journal From Scientific American
|
February 11, 1998
High-dose aldesleukin in renal cell carcinoma: long-term survival update
R I Fisher, S A Rosenberg, M Sznol, et al.
Human Gene Therapy
|
January 1, 1995
A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401
R T Fenton, M Sznol, D G Luster, et al.
Annals of Internal Medicine
|
July 15, 1989
Adrenal insufficiency and interleukin-2 therapy
L A VanderMolen, J W Smith, D L Longo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1995
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
G Fyfe, R I Fisher, S A Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1996
Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy
G A Fyfe, R I Fisher, S A Rosenberg, et al.
Cancer Research
|
May 1, 1992
Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study
W J Urba, C Ewel, W Kopp, et al.
Cancer Research
|
May 15, 1990
Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine
W J Urba, L C Hartmann, D L Longo, et al.
Page
of 7